Hangzhou Just Bio Raises $35 Million for Biologics in B+ Round

04:49 EDT 7 Jun 2018 | ChinaBio Today

Hangzhou Just Biotherapeutics completed a $35 million Series B+ round to develop its global antibody and recombinant protein biologic drug portfolio. The funding is in addition to the $57 million B round announced last year. Formed as a JV with Just Bio of Seattle, Hangzhou Just is led by industry veterans who want to optimize development and manufacturing of biologic drugs, making the products more affordable. Hillhouse Capital of Beijing led the B+ round. The company plans to form partnerships to speed its growth. More details....

Share this with colleagues:

Original Article: Hangzhou Just Bio Raises $35 Million for Biologics in B+ Round


More From BioPortfolio on "Hangzhou Just Bio Raises $35 Million for Biologics in B+ Round"

Quick Search


Relevant Topics

Biotechnology Products
BioPortfolio lists over 550 biotechnology products - please open Direct topic pages: Actos Advair Biopharmaceuticals Biosimilars Biotherapeutics GMO Crops Lipitor ...

An antibody is a protein produced by the body's immune system when it detects harmful substances, called antigens. Examples of antigens include microorganisms (such as bacteria, fungi, parasites, and viruses) and chemicals. Antibodies may be produc...

Recombinant DNA
Recombinant DNA is the formation of a novel DNA sequence by the formation of two DNA strands. These are taken from two different organisms. These recombinant DNA molecules can be made with recombinant DNA technology. The procedure is to cut the DNA of ...